Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.40 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.40 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.39 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1073479 | 1.00 | PRCP (0.44) | PRCPSLC6A2SLC6A3SLC6A4TLR2 | |
| Hydrochloric Acid SCHEMBL3530351 | 1.00 | PRCP (0.44) | PRCPSLC6A2SLC6A3SLC6A4TLR2 | |
| SCHEMBL115996 | 0.98 | PRCP (0.45) | PRCPSLC6A2SLC6A3SLC6A4DPP7 | |
| SCHEMBL10829027 | 0.98 | PRCP (0.45) | PRCPSLC6A2SLC6A3SLC6A4DPP7 | |
| SCHEMBL3330660 | 0.98 | PRCP (0.45) | PRCPSLC6A2SLC6A3SLC6A4DPP7 | |
| SCHEMBL133135 | 0.98 | PRCP (0.45) | PRCPSLC6A2SLC6A3SLC6A4DPP7 | |
| Ammonia Solution, Strong SCHEMBL6516951 | 0.96 | PRCP (0.44) | PRCPSLC6A2SLC6A3SLC6A4DPP7 | |
| Hydrochloric Acid SCHEMBL1282288 | 0.95 | SLC6A2 (0.46) | PRCPSLC6A2SLC6A3SLC6A4KDM4E | |
| Azetidine SCHEMBL18917062 | 0.95 | PRCP (0.43) | PRCPSLC6A2SLC6A3SLC6A4DPP7 | |
| Hydrochloric Acid SCHEMBL6733273 | 0.95 | SLC6A2 (0.46) | PRCPSLC6A2SLC6A3SLC6A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104926578-A | Preparation method for fatty acyl amide | LANZHOU CHEM PHYS INST | 2015-09-23 | — | — | CN | claimed |
| CN-102731454-B | Dehydrocostunolide derivative, its pharmaceutical composition, preparation method and application thereof | TIANJIN SUNTECH MEDICINE MARGIN TECHNOLOGY CO LTD | 2015-07-08 | — | — | CN | claimed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250367169-A1 | FORMULATIONS FOR PERSONALIZED METHODS OF TREATMENT | FAETH THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4584247-A2 | HETEROATOM SUBSTITUTED CYCLIC AND ALKYL AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-3806661-B1 | USE OF ANTAGONISTS OF T2R54 | FIRMENICH INCORPORATED (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4566459-A2 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | Firmenich Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2025-05-13 | — | — | US | disclosed |
| US-12220402-B2 | Formulations for personalized methods of treatment | FAETH THERAPEUTICS, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20250020651-A1 | PERSONALIZED MODULATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-119264123-A | Antagonists of T2R54, compositions thereof and uses thereof | 弗门尼舍公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-0618894-A1 | NEW TETRAHYDRONAPHTHALENE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993012070-A1 | NEW TETRAHYDRONAPHTHALENE DERIVATIVES | RICHTER GEDEON VEGYSZETI GYÁR RT. (HU) | 1993-06-24 | — | — | WO | disclosed |
| WO-1992015608-A1 | N-(α-SUBSTITUTED-PYRIDINYL)CARBONYL DIPEPTIDE ANTIHYPERTENSIVE AGENTS | LACER S.A. (ES) | 1992-09-17 | — | — | WO | disclosed |
| EP-0104532-B1 | O-HALOBENZOIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, HERBICIDAL COMPOSITIONS AND THEIR USE | Nippon Kayaku Kabushiki Kaisha (JP) | 1986-12-03 | — | — | EP | disclosed |
| US-4590178-A | DIURETICS | AJINOMOTO COMPANY, INCORPORATED (JP) | 1986-05-20 | — | — | US | disclosed |
| US-4536395-A | DIPEPTIDES | AJINOMOTO CO., INC. (JP) | 1985-08-20 | — | — | US | disclosed |
| US-4531964-A | Heterocyclic compound and a herbicidal composition containing said compound | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1985-07-30 | — | — | US | disclosed |
| US-4472381-A | Amino acid derivatives, methods of preparing said derivatives and antihypertensive drugs containing them | AJINOMOTO COMPANY INCORPORATED (JP) | 1984-09-18 | — | — | US | disclosed |
| EP-0104532-A1 | O-Halobenzoic acid derivatives, process for their preparation, herbicidal compositions and their use | Nippon Kayaku Kabushiki Kaisha (JP) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | SLC6A2 1633/4885SLC6A3 1192/4885SLC6A4 860/4885 |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | SLC6A2 512/4885SLC6A3 258/4885SLC6A4 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.